Wagenlehner, Florian M. E.van Oostrum, EdgarTenke, PeterTandogdu, ZaferCek, MeteGrabe, MagnusWullt, Bjorn2024-06-122024-06-1220130302-28381873-7560https://doi.org/10.1016/j.eururo.2012.06.003https://hdl.handle.net/20.500.14551/23378Background: Infection is a serious adverse effect of prostate biopsy (P-Bx), and recent reports suggest an increasing incidence. Objective: The aim of this multinational multicentre study was to evaluate prospectively the incidence of infective complications after P-Bx and identify risk factors. Design, setting, and participants: The study was performed as an adjunct to the Global Prevalence Study of Infections in Urology (GPIU) during 2010 and 2011. Men undergoing P-Bx in participating centres during the 2-wk period commencing on the GPIU study census day were eligible. Outcome measurements and statistical analysis: Baseline data were collected and men were questioned regarding infective complications at 2 wk following their biopsy. The Fisher exact test, Student t test, Mann-Whitney U test, and multivariate regression analysis were used for data analysis. Results and limitations: A total of 702 men from 84 GPIU participating centres worldwide were included. Antibiotic prophylaxis was administered prior to biopsy in 98.2% of men predominantly using a fluoroquinolone (92.5%). Outcome data were available for 521 men (74%). Symptomatic urinary tract infection (UTI) was seen in 27 men (5.2%), which was febrile in 18 (3.5%) and required hospitalisation in 16 (3.1%). Multivariate analysis did not identify any patient subgroups at a significantly higher risk of infection after P-Bx. Causative organisms were isolated in 10 cases (37%) with 6 resistant to fluoroquinolones. The small sample size per participating site and in compared with other studies may have limited the conclusions from our study. Conclusions: Infective complications after transrectal P-Bx are important because of the associated patient morbidity. Despite antibiotic prophylaxis, 5% of men will experience an infective complication, but none of the possible factors we examined appeared to increase this risk. Our study confirms a high incidence of fluoroquinolone resistance in causative bacteria. (C) 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.en10.1016/j.eururo.2012.06.003info:eu-repo/semantics/closedAccessProstate BiopsyInfective ComplicationsUrinary Tract InfectionAntibiotic ResistanceUrinary-Tract-InfectionsEscherichia-ColiAntibiotic-ProphylaxisRisk-FactorsResistantCiprofloxacinPathogensArticle633521527Q1WOS:0003141071000262-s2.0-8487296776322704727Q1